World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 11 June 2018
Main ID:  EUCTR2016-003246-93-PL
Date of registration: 13/12/2016
Prospective Registration: Yes
Primary sponsor: Astrazeneca AB
Public title: The purpose of this study is to investigate how a new experimental medication called anifrolumab is distributed in the body when given as subcutaneous (under the skin) injections to subjects with the autoimmune disease called Systemic Lupus Erythematosus (SLE), also known as Lupus. The study will also explore if anifrolumab may improve Lupus skin symptoms.
Scientific title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in Adult Systemic Lupus Erythematosus Subjects with Type I Interferon test high result and active skin manifestations
Date of first enrolment: 26/01/2017
Target sample size: 32
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003246-93
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: yes
Other trial design description: Sponsor will be unblinded after all patients complete week 12 visit.
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 4
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Hungary Korea, Republic of Poland United States
Contacts
Name: Clinical Trial Transparency   
Address:  Karlebyhus, Astraallén 151 85 Södertälje Sweden
Telephone:
Email: ClinicalTrialTransparency@astrazeneca.com
Affiliation:  AstraZeneca
Name: Clinical Trial Transparency   
Address:  Karlebyhus, Astraallén 151 85 Södertälje Sweden
Telephone:
Email: ClinicalTrialTransparency@astrazeneca.com
Affiliation:  AstraZeneca
Key inclusion & exclusion criteria
Inclusion criteria:
1. Age 18 through 70 years
2. Diagnosis of paediatric or adult SLE for > 24 weeks and fulfilling =4 of the 11 ACR classification criteria with at least one being:
-Positive antinuclear antibody (ANA) or
-Elevated anti-dsDNA antibodies or
-anti-Smith (anti-Sm) antibodies
3. Interferon high test result
4. CLASI activity score = 10
5. Currently receiving at least 1 of the following for treatment of SLE:
• Oral prednisone or equivalent of =40 mg/day) for a minimum of 2 weeks prior to signing the ICFand with stable dosefor at least 2 weeks prior to randomization
• Any of the following medications for at least 12 weeks prior to signing the ICF, and at a stable doses for at least 8 weeks prior to randomization:
(i) Azathioprine =200 mg/day
(ii) Antimalarials (eg, chloroquine, hydroxychloroquine, quinacrine)
(iii) Mycophenolate mofetil =2 g/day or mycophenolic acid =1.44 g/day
(iv) Oral, subcutaneous (SC), or intramuscular methotrexate =25 mg/week
(v) Mizoribine =150 mg/day
6. Must not have signs of active or latent TB.
7. Must not be pregnant or breastfeeding



Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 28
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 4

Exclusion criteria:
1. Active severe or unstable neuropsychiatric SLE
2. Active severe SLE-driven renal disease
3. Any severe herpes infection at any time
4. HBV, HCV, or HIV infection.
5. Known history of a primary immunodeficiency (splenectomy, or any underlying condition predisposing for infection
6. Receipt of any investigation product within 4 weeks or 5 half -lives prior to signing of the ICF
7. History of cancer, apart from:
- Squamous or basal cell carcinoma of the skin if successfully treated
- Cervical cancer in situ if successfully treated






Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Systemic Lupus Erythematosus
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Intervention(s)

Product Name: Anifrolumab
Product Code: MEDI-546
Pharmaceutical Form: Solution for injection
INN or Proposed INN: ANIFROLUMAB
CAS Number: 1326232-46-5
Current Sponsor code: MEDI-546
Other descriptive name: Immunoglobulin G1, anti-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546-chain, dimer
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Primary Outcome(s)
Main Objective: To characterize the pharmacokinetics and pharmacodynamics of anifrolumab.
Primary end point(s): • Anifrolumab concentration and PK parameters, e.g., maximum concentration (Cmax) after first IP dose and trough concentration (Ctrough) after subsequent dosing. Additional PK parameters may be determined where appropriate.
• 21-gene type I IFN signature score and neutralization ratio (relative to baseline)

Secondary Objective: 1. To characterize the safety and tolerability anifrolumab
2. To characterize the immunogenicity of anifrolumab
Timepoint(s) of evaluation of this end point: 12 Weeks
Secondary Outcome(s)
Secondary end point(s): Safety and tolerability variables including:
• Adverse events (AEs) and serious adverse events (SAEs)
• Adverse events of special interest (AESIs) including herpes zoster, influenza, opportunistic infections, tuberculosis (TB), malignancies, non-SLE related vasculitis, anaphylaxis, and major adverse cardiovascular events (MACE)
• Laboratory variables
• Physical examinations
• Vital signs
• ECG
Immunogenicity as assessed by measurement of anti-drug antibodies (ADA).
Timepoint(s) of evaluation of this end point: 52 weeks
Secondary ID(s)
2016-003246-93-HU
D3461C00008
Source(s) of Monetary Support
AstraZeneca
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history